Propanc Biopharma Inc (PPCB)

[aheckler1]

"In further news, the Company has confirmed a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, towards the end of April. The purpose of this meeting is to discuss the Company's ongoing development activities for PRP, including preparation and structure of animal safety/toxicology studies and its proposed early stage patient trials, together with supporting activities."

"We're making significant progress with PRP development and will continue to advance towards patients trials at the earliest opportunity," said James Nathanielsz, Propanc's Chief Executive Officer. "Meeting with the MHRA represents a significant milestone for the Company and will confirm our future plans. Together with the enhancement of our intellectual property portfolio and plans to seek orphan drug designation, we're at the right time to initiate discussions with potential licensing partners looking to add a new therapeutic drug class to their portfolio. Whilst we intend to hold these discussions soon, I'm pleased to confirm that we're sufficiently capitalized to progress towards patient trials and have every intention of funding the early stage clinical development of PRP."

"Propanc aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020."

http://finance.yahoo.com/news/propanc-confirms-prp-response-broad-133000743.html